Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04710342
Other study ID # CAP0001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 21, 2021
Est. completion date December 31, 2023

Study information

Verified date February 2023
Source Praxis Medical Devices Ltd
Contact Brendan McLaughlin
Phone 353872471662
Email brendanmclaughlin1@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study represents a prospective, non-randomized, dual-center clinical study to evaluate the safety and effectiveness of the CapBuster System in crossing a de novo or restenotic infrapopliteal chronic total occlusion. Measures of safety and efficacy will be assessed through 30 days post-intervention.


Description:

The diagnostic and interventional procedure can be conducted via contralateral or antegrade approach and arterial access will be obtained utilizing standard percutaneous techniques and devices. Baseline angiographic images will be obtained prior to the study intervention to confirm the presence of a peripheral arterial occlusion. These images will include the target lesion as well as inflow and outflow with ipsilateral run off to the distal foot. If angiographic imaging confirms that the subject meets enrollment criteria, the enrolled subject will then undergo the study procedure. If the investigator determines that treatment is required of non-target arterial lesions, the treatment may be performed during the study index procedure according to the investigator's standard practices using commercially available devices. Prior to utilization of the CapBuster system, the investigator will attempt to cross the target lesion CTO utilizing conventional catheters and guidewires. To minimize vessel trauma, attempted guidewire crossing time will be limited to no more than 5 minutes. The crossing time will begin when the guidewire reaches the lesion CTO cap and will end after occlusion is successfully crossed with confirmed wire placement in the true lumen. If successful crossing is achieved with a conventional guidewire, the CapBuster system will not be utilized. The subject will be a screen failure and will not be considered enrolled in the trial. If crossing attempt is not successful with a conventional guidewire, the CapBuster system will be utilized. A subject is considered enrolled in the study upon introduction of the CapBuster system into the subject's vasculature. The CapBuster support catheter will be inserted over a conventional guidewire and advanced until the distal tip reaches the CTO cap. The CapBuster 3.0 mm diameter balloon is then inflated to stabilize the system within the arterial vessel. The conventional guidewire is replaced with the CapBuster penetrating wire and, under fluoroscopic guidance, the penetrating wire is manually rotated to penetrate the CTO cap. The balloon pressure may be increased to ensure proper apposition with the vessel wall and maximize stability. Following penetration of the cap, the penetrating wire is replaced with a conventional steerable guidewire. Standard wire escalation techniques will be utilized for continued advancement of the conventional guidewire and complete crossing of the occlusion. Angiography is performed to confirm guidewire placement. Successful crossing is defined as guidewire placement within the true lumen proximal and distal to the target lesion without utilization of a re-entry device. After successful crossing is achieved, the target lesion may be treated per Investigator discretion with commercially available devices.


Recruitment information / eligibility

Status Recruiting
Enrollment 26
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Males > 18 years of age and Female patients of non child-bearing potential 2. Clinical diagnosis of peripheral arterial disease requiring revascularization as evidenced by Duplex UltraSound, Digital Subtraction Angiography, CT angiography, or MR angiography 3. Rutherford Classification 2-5 4. Presence of infrapopliteal arterial de novo or restenotic chronic total occlusion(s) (100% stenosis), with TIMI 0 flow, confirmed by angiography. Vessel distal to the occlusion(s) must be visualized per collateral or retrograde flow. A maximum of 2 target occlusions can be treated per patient. Target occlusion(s) can be in-stent restenosis 5. Target vessel(s) must be = 2.5 mm and = 3.25 mm in diameter proximal to the target occlusion(s) by visual estimate 6. Target occlusions(s) cannot be crossed by conventional guidewire (crossing time limited to =5 minutes) 7. In the opinion of the investigator, life expectancy of > 1 year 8. Willing and able to sign the informed consent form Exclusion Criteria: 1. Target occlusion is within a bypass graft 2. Target occlusion can be crossed by conventional guidewire 3. Target occlusion is below tibiotalar joint 4. Presence of acute limb ischemia 5. Known sensitivity or allergy to contrast materials that cannot be adequately pre-treated 6. Known allergy or contraindication to all antiplatelet therapy 7. Subject has signs or symptoms of systemic infection/sepsis (temperature =38.0o Celsius and WBC =12,000 cells/uL). If subject has localized infection, including cellulitis or osteomyelitis, or infection is adequately treated and controlled, per investigator discretion, patient may be enrolled. 8. Known or suspected myocardial infarction or stroke within previous 30 days 9. Significant acute or chronic renal disease with a GFR <30 mL/min/1.73m2 10. History of a surgical or endovascular procedure on the target limb within 30 days of the index procedure or non-target limb within 2 weeks of the index procedure 11. Planned surgical or endovascular procedure prior to the subject's 30-day follow-up. Planned minor amputations are allowed. 12. Subject is scheduled for a target limb major amputation (above the ankle) within 30 days post study procedure 13. Currently participating in another investigational drug or device study 14. Unwilling or unable to comply with the protocol or follow-up requirements 15. Any concurrent medical, psychological, or social condition, which may significantly interfere with the subject's optimal participation in the study, in the opinion of the investigator 16. Female patients of child-bearing potential.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CapBuster
Evaluate the safety and effectiveness of the CapBuster System in crossing de novo or restenotic chronic total occlusions in infrapopliteal peripheral arteries.

Locations

Country Name City State
Netherlands St Antonius Ziekenhuis, Koekoekslaan 1, 3435 CM Nieuwegein

Sponsors (3)

Lead Sponsor Collaborator
Praxis Medical Devices Ltd Ospedale Regionale di Lugano, St. Antonius Hospital

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary CTO Crossing Successful crossing of the targeted chronic total occlusion, defined as angiography confirmed guidewire placement in the true lumen without utilization of a re-entry device. 12 months
Secondary CapBuster system safety from perforations Freedom from CapBuster System related clinically significant perforations that require intervention 12 months
Secondary CapBuster system safety from embolizations Freedom from CapBuster System related clinically significant embolizations that require intervention 12 months
Secondary CapBuster system safety from dissections Freedom from CapBuster System related clinically significant flow-limiting (type C, D, E) dissections that require intervention. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05111496 - Evaluation of the Radiological Dose Delivered to Risky Interventional Cardiology Patients (Optidose)
Not yet recruiting NCT05440084 - Impact of CTO PCI (Chronic Total Occlusion Percutaneous Intervention) on Regular Physical Activity
Withdrawn NCT04059536 - Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)
Completed NCT05158686 - Use of Drug-Coated Balloon to Improve Recanalization of a Coronary Chronic Total Occlusion After Failed Angioplasty
Completed NCT03988166 - Chronic Total Occlusion Percutaneous Coronary Intervention Study N/A
Not yet recruiting NCT06175377 - Antiplatelet Therapy After Successful Percutaneous Coronary Intervention for Chronically Occluded Coronary Artery N/A
Not yet recruiting NCT05632653 - CTO-PCI in Heart Failure Patients N/A
Recruiting NCT03563989 - STENTYS Xposition S in the Treatment of Chronic Total Artery Occlusion N/A
Not yet recruiting NCT06358508 - Sapphire 3 CTO Study N/A
Completed NCT01246505 - Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions Phase 3
Recruiting NCT05614180 - Chronic Total Occlusive Lesions CMR Study
Completed NCT04226326 - Investigating the Utility of Remote Index of Microvascular Resistance in Patients With Chronic Total Occlusion N/A
Recruiting NCT04533633 - German Epicardial Collateral CTO Registry
Recruiting NCT04650139 - Coronary Interventions Ulm - Coronary Chronic Total Occlusions
Recruiting NCT06137521 - Risk Factors and Outcomes in Coronary Chronic Total Occlusion
Completed NCT02358629 - A Prospective, Non-randomized Study to Evaluate the Safety and Performance of the NovaCross™ Microcatheter in Femoropopliteal Chronic Total Occlusion (CTO). N/A
Completed NCT00670436 - The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions Phase 2
Completed NCT04862559 - A Single Center Study to Evaluate the Safety of the NovaCross Microcatheter in Crossing Chronic Total Occlusions N/A
Active, not recruiting NCT02227771 - Consistent CTO Trial N/A
Recruiting NCT05458999 - Decreasing Patient Anxiety During Revascularization of Chronic Total Coronary Occlusions Using Virtual Reality Glasses. N/A